

Steve Sisolak  
Governor

Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

**Silver State Script Board**

**Draft Meeting Minutes**

**Date of Meeting:** Thursday, July 29, 2021, at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

Agenda Item	Record	Notes																														
<b>Closed Executive Session</b>																																
Financial Review of Drug Classes with Proposed Changes	<p>Chairman Decerbo called the meeting to order at 1:05 PM on July 29, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table border="0"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>The DHCFP Staff Present were as follows:</b></p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Berntson, Kindra, Social Services Program Specialist II</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</p> <p>Capurro, Antonina, Deputy Administrator</p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
	<p>A quorum was present.</p> <p>Chairman Decerbo directed Mr. Kevin Whittington to proceed with the Financial Review of Drugs classes with proposed changes up for review during the Second Quarter 2021 Silver State Scripts Board meeting.</p> <p>Mr. Whittington reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside of this closed session of the Silver States Script Board meeting.</p> <p>Mr. Whittington informed the board the recommendation for the Proposed new class Cardiovascular Agents - Antilipemics - PCSK9 Inhibitors was to defer action at this time; as such, no financial review was presented.</p> <p>Mr. Whittington presented the Financial Review of the Neurological Agents - Anti-Migraine Agents - Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Gastrointestinal Agents - Functional Gastrointestinal Disorder Drugs class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Analgesics Opiate Agonists - Abuse-Deterrent class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Analgesics Opiate Agonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Ophthalmic Agents - Antiglaucoma Agent class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the Financial Review of the Psychotropic Agents - Antipsychotics - Atypical Antipsychotics - Oral class noting the products with proposed changes in PDL status.</p>	<p><b>Gainwell Technology Staff Present were as follows:</b> Leid, Jovanna, Pharm.D.</p> <p><b>OptumRx Staff Present were as follows:</b> Whittington, Kevin, R.Ph. Kiriakopoulos, Amanda, Pharm.D. LeCheminant, Jill, Pharm.D Chien, Michael, Pharm.D. Piccirilli, Annette Medina, Daniel</p>

Agenda Item	Record	Notes																														
	<p>Mr. Whittington presented the Financial Review of the Dermatological Agents - Topical Anti-infectives - Topical Scabicides class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington concluded the financial reviews and Chairman Decerbo directed the Board members to transition to the open session of the Silver States Script Board Meeting.</p>																															
<b>Open Public Meeting</b>																																
<p>1. Call to Order and Roll Call</p>	<p>Chairman Decerbo called the meeting to order at 1:35 PM on July 29, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table data-bbox="661 613 1396 1019"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>A quorum was present.</p>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>The DHCFP Staff Present were as follows:</b>  Olsen, David, Social Services Chief III  Gudino, Antonio, Social Services Program Specialist III  Berntson, Kindra, Social Services Program Specialist II  Flowers, Ellen, Program Officer I  Lither, Gabriel, SDAG  Capurro, Antonina, Deputy Administrator</p> <p><b>Gainwell Technology Staff Present were as follows:</b>  Leid, Jovanna, Pharm.D.</p> <p><b>OptumRx Staff Present were as follows:</b>  Kiriakopoulos, Amanda, Pharm.D.  LeCheminant, Jill, Pharm.D.  Whittington, Kevin, R.Ph.  Piccirilli, Annette  Medina, Daniel</p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Khurana, Sapandeep, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
		<p>Hansen, Sean Lee, Cara, Pharm.D. Chien, Michael, Pharm.D.</p> <p><b>The public attendee list is included as Attachment A.</b></p> <p><b>Note:</b> Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet the accuracy of the attendee list is not assured.</p>
2. Public Comment on Any Matter on the Agenda.	<p>Telephonic and web comment was called for and the phone lines were opened.</p> <p>No public comment was offered.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from March 25, 2021.	<p>No corrections were offered.</p> <p>The minutes were approved by unanimous consent.</p>	
b. Status Update by the DHCFP.	<p>Chief David Olsen announced Dr. Antonina Capurro as the new Acting Deputy Administrator. Dr. Capurro introduced herself. Chief Olsen discussed Senate Bill 190 and Senate Bill 325 passed legislation, which allows for the creation of a new pharmacist provider type to increase access to self-administered hormonal contraceptives, HIV prevention medication, and laboratory tests. Chief Olsen stated that pharmacists will have the ability to prescribe and dispense these medications and regulations for this process will be developed by the board of pharmacy. Chief Olsen announced Senate Bill 380 passed, which addresses increased drug transparency in Nevada. Chief Olsen updated the Board that the</p>	<p>Referenced web addresses:</p> <p>The Nevada Department of Health and Human Services, Division of Health Care Financing and Policy Provider Portal. <a href="https://www.medicaid.nv.gov/">https://www.medicaid.nv.gov/</a></p>

Agenda Item	Record	Notes
	<p>onboarding process began with the new pharmacy benefit manager, Magellan. Chief Olsen expressed appreciation to Dr. Carl Jeffery for his service to the State of Nevada and informed the Board that he is no longer supporting Nevada Medicaid with OptumRx. Chief Olsen announced DuAne Young's, the former Deputy Administrator, role as the Director of Policy.</p> <p>Mr. Antonio Gudino and Chairman Decerbo thanked Dr. Chu for her service and extended best wishes, as this is her last meeting as a board member.</p> <p>Roll call was taken of meeting participants.</p>	<p>The Division of Health Care Financing and Policy  <a href="http://dhcfnv.gov/">http://dhcfnv.gov/</a></p>
4. Proposed New Drug Classes		
a. For Possible Action: Discussion and possible adoption of Cardiovascular Agents - Antilipemics - PCSK9 Inhibitors.		
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Mr. Ben Droese with Amgen Medical Affairs, thanking the committee for adding Repatha to the PDL.</p>	
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed the administration of class agents via subcutaneous injection and efficacy in LDL reduction. Dr. Kiriakopoulos highlighted clinical guidelines recommendation of maximally tolerated statins as first-line therapy, and ezetimibe or the PSK9 inhibitors are recommended as potential second-line agents.</p> <p>Dr. Kiriakopoulos recommended the board consider the class clinically and therapeutically equivalent.</p>	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Chu seconded the motion.</p>	

Agenda Item	Record	Notes																												
<p>equivalency of agents in class.</p>	<p>A vote was held:</p> <table border="0" data-bbox="661 272 1501 557"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. Kiriakopoulos recommended adding Praluent and Repatha as preferred.</p>																													
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Crumby moved to accept the recommendations.</p> <p>Board Member Adashek seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 889 1501 1174"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>5. Established Drug Classes Being Reviewed Due to the Release of New Drugs</p>																														
<p>a. For Possible Action: Discussion and possible adoption of Neurological Agents - Anti-Migraine</p>																														

Agenda Item	Record	Notes
Agents - Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists.		
i. Public comment.	<p>The following written public comment is attached hereto:</p> <ol style="list-style-type: none"> <li>1) Aimovig package insert from Droese, Ben of Amgen Medical Administration</li> <li>2) Letter dated June 16, 2021, from Nguyen, Quang, DO of Las Vegas Endocrinology</li> <li>3) Letter dated June 17, 2021, from Lee, Katrina, APRN</li> <li>4) Letter dated June 14, 2021, from Thai, Danny of 986 Specialty Pharmacy</li> </ol> <p>The public comments referenced above were highlighted on the record for members of the Board by Dr. Kiriakopoulos.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Mr. Droese of Amgen Medical Administration providing information for Aimovig. Mr. Droese reviewed package insert information for Aimovig. Mr. Droese discussed the American Headache Society's updated consensus statement on integrating new migraine treatments into clinical practice and an update to new preventative CGRP inhibitors. Trials demonstrating the safety and efficacy of Aimovig were presented. Mr. Droese requests that Aimovig is added to the PDL.</p> <p>Comment was made from Ms. Jennifer Shear of Teva pharmaceutical providing information on Ajovy. Ms. Shear reviewed package insert information for Ajovy. Trials demonstrating the safety and efficacy of Ajovy were presented. Ms. Shear requests Aimovig be added to the PDL.</p>	

Agenda Item	Record	Notes																												
	Comment was made from Ms. Jenna Gianninoto of AbbVie medical affairs noting her availability to answer questions regarding Ubrelyvy.																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed the new product, Vyepti, the mechanism of action, indication, administration, and two trials demonstrating efficacy. Dr. Kiriakopoulos discussed the classification of CGRP agents and showed various classification models.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Hautekeet moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Adashek seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 776 1503 1062"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended adding Vytepi as non-preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the proposed changes.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p>																													



Agenda Item	Record	Notes																												
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
6. Established Drug Classes																														
a. For Possible Action: Discussion and possible adoption of Gastrointestinal Agents - Functional Gastrointestinal Disorder Drug.																														
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made from Ms. Gianninoto of AbbVie medical affairs noting her availability to answer questions regarding Linzess.</p>																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos briefly discussed the indications for the agents in the functional gastrointestinal disorder class.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Chu moved to accept that the list is clinically and therapeutically equivalent.</p> <p>Board Member Adashek seconded the motion.</p> <p>A vote was held:</p>																													

Agenda Item	Record	Notes																												
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended the Board add the lubiprostone to non-preferred and maintaining Amitiza as preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the proposed updates as presented.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
b. For Possible Action: Discussion and possible adoption of Analgesics - Opiate Agonists - Abuse-Deterrent.																														
i. Public comment.	The following written public comment is attached hereto:																													

Agenda Item	Record	Notes																												
	<p>1) Sublocade package insert from submitted.</p> <p>The public comment referenced above was highlighted on the record for members of the Board by Dr. Kiriakopoulos.</p> <p>Chairman Decerbo questioned if Sublocade will be reviewed at an upcoming meeting. Dr. Kiriakopoulos stated that she will research when Sublocade will be reviewed.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Kiriakopoulos discussed Hysingla ER. Generic hydrocodone bitartrate is available.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="653 1101 1503 1378"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																												
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended removing Embeda and Morphabond as preferred and Arymo ER as non-preferred as these products are no longer manufactured. Dr. Kiriakopoulos recommended adding hydrocodone bitartrate as non-preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 561 1503 841"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
c. For Possible Action: Discussion and possible adoption of Analgesics - Opiate Agonists																														
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed Zohydro ER. Generic hydrocodone bitartrate is available.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.																													

Agenda Item	Record	Notes																												
<p>clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 625"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. Kiriakopoulos recommended adding hydrocodone bitartrate to non-preferred.</p>																													
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 966 1501 1242"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>d. For Possible Action: Discussion and possible adoption of Ophthalmic Agents – Antiglaucoma Agents.</p>																														

Agenda Item	Record	Notes																												
i. Public comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed Brimonidine and Brinzolamide. Generic products brimonidine tartrate ophthalmic solutions 0.2% and 1% are available.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Crumby moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 813 1503 1089"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Kiriakopoulos recommended moving Brimonidine to non-preferred and adding Brinzolamide to non-preferred. Alphagan P and Azopt to remain preferred.</p>																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p>																													

Agenda Item	Record	Notes																												
	<table border="1"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>e. For Possible Action: Discussion and possible adoption of Psychotropic Agents – Antipsychotics - Atypical Antipsychotics – Oral.</p>																														
<p>i. Public comment.</p>	<p>The following written public comment is attached hereto:</p> <ol style="list-style-type: none"> <li>1) Letter dated June 7, 2021, from Mahakian, Charles, MD</li> <li>2) Letter dated June 7, 2021, from Raini, Francis, APRN</li> <li>3) Letter dated June 8, 2021, from Anooshian, John, MD</li> <li>4) Letter dated June 2, 2021, from Tan, Rhigel, APRN</li> <li>5) Letter dated June 2, 2021, from Ramirez, Ruth, APRN</li> <li>6) Letter dated June 9, 2021, from Zafar, Uzma MD</li> <li>7) Letter dated May 25, 2021, from Duncan, Cameron, DNP</li> <li>8) Letter dated June 4, 2021, from Lynch, M.</li> <li>9) Letter dated June 4, 2021, from Stoll, Kathi</li> <li>10) Letter dated June 4, 2021, from Steinagel, Gerri, MD</li> <li>11) Letter dated June 4, 2021, from Luback-Neves, Marie, DNP</li> <li>12) Letter dated June 4, 2021, from Price, Charles, MD</li> <li>13) Letter dated June 9, 2021, from Dr. Vuppalapati</li> <li>14) Letter dated June 10, 2021, from Evans, Jennifer, PMHNP</li> <li>15) Letter dated May 25, 2021, from Stolzner, Pauline, APRN</li> <li>16) Letter dated June 8, 2021, from Nguyen, Paul, MD</li> </ol>																													

Agenda Item	Record	Notes
	<p>17) Letter dated June 7, 2021, from Ortega, Luis Carlos, MD  18) Letter dated May 28, 2021, from Cruvey, Karen, MD  19) Letter dated June 7, 2021, from Horne, Robert Lynn, MD  20) Package insert for Perseris</p> <p>The public comments referenced above were highlighted on the record for members of the Board by Dr. Kiriakopoulos.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Dr. Ruth Ramirez of Psychiatrist Solutions Clinic requesting Caplyta as a preferred drug. Information was provided on favorable outcomes for patients on Caplyta treatment.</p> <p>Comment was made by Dr. Paul Nguyen requesting Caplyta be a preferred drug. Concern was expressed on patient relapse after hospitalization if Caplyta is not accessible. Information was provided on favorable outcomes for patients on Caplyta treatment.</p> <p>Comment was made from Ms. Gianninoto of AbbVie medical affairs noting her availability to answer questions regarding Vraylar.</p> <p>Comment was made by Ms. Robin Reedy of NAMI Nevada. NAMI supports open access to all safe and effective medications for mental health conditions as prescribed by qualified health care professionals. Open access allows patients to receive the medication that works best for that individual patient. Ms. Reedy discussed Nevada's last-place ranking in mental health services due to restricted access to medications, number of providers, and lack of pediatric services.</p> <p>Comment was made by Ms. Micah Lands, MSL. Caplyta package insert information was reviewed. Trials demonstrating safety and efficacy of</p>	



Agenda Item	Record	Notes																												
	Caplyta were presented. Ms. Lands requests Caplyta be considered when making formulary decisions.																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Kiriakopoulos discussed indications of Invega, Saphris, and Secuado. Generic options for these products are available. Asenapine patch and ODT formulations were reviewed.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 740 1503 1019"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Kiriakopoulos recommended including “topical” in the title for this class for clarification purposes. Recommendation made to move Invega to preferred and add asenapine to non-preferred.																													

Agenda Item	Record	Notes
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board member Adashek moves to accept the proposed changes and move Caplyta to preferred due to the number of providers that have taken the time to make this request.</p> <p>Board Member Ward seconded the motion.</p> <p>Chairman Decerbo expressed appreciation for the Medicaid providers in general and for taking the time to speak with the Board to optimize the formulary.</p> <p>Dr. Kiriakopoulos reviewed the PDL categories, noting non-preferred agents are part of the PDL and are available through the PA process if there is a medically justifiable reason a non-preferred product is needed over a preferred product. Dr. Kiriakopoulos discussed Medicaid formularies that have open access to mental health medications still have criteria around safety and other edits, and commented on the large number of preferred products on the Nevada Medicaid formulary.</p> <p>Board member Adashek discussed the difficulties and concerns with this class of medications and the requirement for members to try and fail preferred agents before accessing the non-preferred agents.</p> <p>Dr. Kiriakopoulos agreed with the concern and notes that finding an agent that works for the patient is often done through trial and error.</p> <p>Chairman Decerbo discussed pharmacogenomics and the future potential to eliminate the need for trial and error. The increased coverage provided with the addition of Invega to preferred products is noted.</p> <p>Board member Chu asks for clarification on the advantage of Caplyta as a first-line agent.</p>	

Agenda Item	Record	Notes																												
	<p>Dr. Nguyen responds that, in his clinical experience, patients using Caplyta have a good response to the medication because Caplyta negates metabolic side effects seen with other agents. Dr. Nguyen notes member medication compliance is better with Caplyta.</p> <p>Dr. Ramirez comments that patients experience less weight gain with Caplyta and notes members who gain weight due to medication often stop therapy without informing their provider. Dr. Ramirez states there is less cardiovascular risk with Caplyta, making it a safer option.</p> <p>Mr. Gabriel Lither asked if the motion from board member Adashek was seconded. Chairman Decerbo confirms the motion was seconded by board member Ward. Mr. Lither requests clarification from Board member Adashek on the intention of the motion. Board member Adashek commented he intended to recommend Caplyta as preferred.</p> <p>Board member Adashek amends the motion to move Caplyta to preferred.</p> <p>Board member Ward second the motion.</p> <p>A vote was held:</p> <table data-bbox="653 987 1501 1268"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																												
	<p>Board Member Hautekeet moved to accept the changes as presented: to add “topical” to the drug class name, add Invega to preferred, and add asenapine to non-preferred.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 492 1501 771"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumbly, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumbly, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumbly, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
<p>f. For Possible Action: Discussion and possible adoption of Dermatological Agents – Topical Anti-Infectives – Topical Scabicides.</p>																														
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Kiriakopoulos discussed Sklice. Generic ivermectin is available.</p> <p>Dr. Kiriakopoulos recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
<p>iii. Discussion by Board and action by Board to approve</p>	<p>Board Member Ward moved to accept the class as clinically and therapeutically equivalent.</p>																													

Agenda Item	Record	Notes																												
<p>clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 625"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. Kiriakopoulos recommended adding ivermectin to non-preferred.</p>																													
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 966 1501 1242"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>7. OptumRx Reports: New Drugs to Market and New Line Extensions</p>	<p>Dr. Kiriakopoulos reviewed teplizumab, a new treatment being launched for the delay of type 1 diabetes. Atogepant, a migraine prophylaxis agent, was noted. Dr. Kiriakopoulos discussed new treatments coming out for atopic dermatitis, including abrocitinib, tralokinumab, and ruxolitinib, and their respective expected indications and mechanisms of action. Dr.</p>																													

	Kiriakopoulos highlighted a new treatment for plaque psoriasis, bimekizumab. Dr. Kiriakopoulos identified generic pipeline medications with their expected availability, including Bepreve, Daliresp, Restasis, Byetta, Chantix, Forteo, intranasal Narcan, and Bystolic.	
8. Closing Discussion		
a. Public comments on any subject.	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was offered.	
b. Date and location of the next meeting.	Chairman Decerbo confirmed the next meeting is scheduled for September 23, 2021, and will be a hybrid meeting.	
c. Adjournment.	Chairman Decerbo adjourned the meeting at 3:02 PM.	

## **Attachment A – Members of the Public in Attendance**

Ashton, Elisa, Johnson and Johnson

Balen, Valerie, Belz Case

Berry, Kenneth

Booth, Robert, AbbVie

Droese, Ben, Amgen

Duerre, Mark, Itci-Inc

Duke, Michelle

Feroli, Joseph, Takeda

Germain, Joe, Biogen

Gianninoto, Jenna, AbbVie

Isaki, Steven, Lundbeck

Kniffin, Jason, Novo Nordisk

Lands, Micah, Itci-Inc

Large, David

Lau, Jimmy

Leroue, Chelsea, Biohaven Pharma

Lovan, Charlie, AbbVie

Nassif, Leila, Amgen

Robinson, Lovell, AbbVie

Nguyen, Paul

Oliver, Carmen, Biohaven Pharma

Ramirez, Ruth

Reedy, Robin, NAMI

Ritter, Jean, Zealand Pharma

Roy, Melissa, Otsuka-US

Shear, Jennifer, Teva Pharm


























Sullivan, Mike, Amgen

Wright, Matthew, Artia Solutions

Zarob, Michael

Attendee with no last name available: Mark

## Attachment B – Submitted Written Comment

-  Ajovy SSSB July 2021 Request for Public Comment
-  Caplyta - RxInfo
-  Caplyta - Scan Jun 15 2021
-  Caplyta - signed caplyta letter. june 2021 doc08336720210609130332
-  Caplyta - SSSB Caplyta
-  caplyta (002)
-  Caplyta Agenda Item 6d
-  Caplyta email 2 2021 06
-  Caplyta email 3 2021 06
-  Caplyta email 4 2021 06
-  Caplyta email 5 2021 06
-  Caplyta email 6 2021 06
-  Caplyta email 7 2021 06
-  Caplyta email 8 2021 06
-  Caplyta email 9 2021 06
-  Caplyta email 2021 06
-  Caplyta IMG\_0001
-  caplyta June 7 Luis Ortega MD\_
-  Caplyta Letter to Committee 5.28.2021
-  CaplytaMedicaidLetter
-  Nurtec email 2021 06
-  Nurtec June 17 Katrina Lee
-  Nurtec-July 2021 SSSB Meeting Written Correspondence - 986 Spec Pharm.docx
-  Perseris Submission for Public Comment
-  Sublocade Submission for Public Comment